

PROGENICS PHARMACEUTICALS INC
 Form 3
 April 01, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Wong Vivien		(Month/Day/Year)	PROGENICS PHARMACEUTICALS INC [PGNX]	
(Last)	(First)	04/01/2015	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
777 OLD SAW MILL RIVER ROAD			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
TARRYTOWN, NY 10591			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
(City)	(State)	(Zip)	(give title below)	(specify below)
			Executive Vice President	
			6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input checked="" type="checkbox"/> Form filed by One Reporting Person	
			<input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,121	D	W

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	--	--	---

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Non-Qualified Stock Option (right to buy)	Â (1)	03/03/2024	Common Stock	127,800	\$ 4.7	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	11/01/2020	Common Stock	25,000	\$ 4.83	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	04/04/2023	Common Stock	48,000	\$ 5.03	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	07/01/2019	Common Stock	3,375	\$ 5.33	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	07/01/2020	Common Stock	6,000	\$ 5.35	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	03/02/2025	Common Stock	66,000	\$ 6.65	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	07/01/2021	Common Stock	60,000	\$ 7.4	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	03/01/2022	Common Stock	40,000	\$ 9.81	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	07/01/2018	Common Stock	2,589	\$ 16.05	D	Â
Non-Qualified Stock Option (right to buy)	Â (3)	11/01/2017	Common Stock	6,000	\$ 22.67	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wong Vivien 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	Â	Â	Â Executive Vice President	Â

Signatures

/s/ Vivien Wong 04/01/2015

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Amount consists of 2 separate grants. 75,000 stock options become exercisable in four equal annual installments and 52,800 become exercisable in three equal annual installments both commencing one year from grant date.
 - (2) The stock options become exercisable in three equal annual installments, commencing one year from the grant date.
 - (3) The stock options become exercisable in five equal installments, commencing one year from the grant date.

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.